{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:34:48Z","timestamp":1787020488503,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravenous drug use (IVDU) represents the major factor of HCV transmission, but the treatment uptake among people who inject drugs (PWID) remains low owing to a false presumption of low efficacy. The aim of our study was to assess treatment efficacy in PWID and factors determining adherence to therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 278 consecutive patients starting DAA (direct-acting antivirals) therapy were included, divided into two groups: individuals with a history of IVDU, PWID group (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009101) and the control group (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009177) without a history of IVDU.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sustained virological response 12\u00a0weeks after the end of therapy (SVR12) was achieved by 99\/101 (98%) and 172\/177 (98%) patients in the PWID and control group, respectively; in PWID group, two patients were lost to follow-up, and in the control group, four patients relapsed and one was lost to follow-up. PWID patients postponed appointments significantly more often, 29 (28.7%) in PWID versus 7 (4%) in the control group,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001. Thirteen of 101 (12.9%) and six of 177 (3.4%) patients in the PWID and in the control group, respectively, missed at least one visit (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). However, postponing visits led to a lack of medication in only one PWID. In the PWID group, older age (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05; OR 1.07, 95% CI 1.00\u20131.20) and stable housing (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01; OR 9.70, 95% CI 2.10\u201356.20) were factors positively contributing to adherence. Contrarily, a stable job was a factor negatively influencing adherence (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05; OR 0.24, 95% CI 0.06\u20130.81). In the control group, none of the analyzed social and demographic factors had an impact on adherence to therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In PWID, treatment efficacy was excellent and was comparable with SVR of the control group. Stable housing and older age contributed to a better adherence to therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-021-00519-y","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T09:02:56Z","timestamp":1625043776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Therapy of chronic hepatitis C in people who inject drugs: focus on adherence"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1462-5920","authenticated-orcid":false,"given":"Sona","family":"Frankova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Jandova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Jinochova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miluse","family":"Kreidlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Merta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sperl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"issue":"12","key":"519_CR1","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Health"},{"key":"519_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"EASL","year":"2018","unstructured":"EASL. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461\u2013511.","journal-title":"J Hepatol"},{"issue":"10","key":"519_CR3","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","volume":"26","author":"J Grebely","year":"2015","unstructured":"Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26(10):1028\u201338.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"519_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.21101\/cejph.a5350","volume":"27","author":"S Frankova","year":"2019","unstructured":"Frankova S, Urbanek P, Husa P, Nemecek V, Razavi H, Razavi-Shearer D, Chlibek R, Sperl J. Chronic hepatitis C in the Czech Republic: forecasting the disease burden. Cent Eur J Public Health. 2019;27(2):93\u20138.","journal-title":"Cent Eur J Public Health"},{"issue":"7350","key":"519_CR5","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1038\/474S18a","volume":"474","author":"BR Edlin","year":"2011","unstructured":"Edlin BR. Perspective: test and treat this silent killer. Nature. 2011;474(7350):S18-19.","journal-title":"Nature"},{"issue":"9791","key":"519_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","volume":"378","author":"PK Nelson","year":"2011","unstructured":"Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571\u201383.","journal-title":"Lancet"},{"issue":"4","key":"519_CR7","doi-asserted-by":"publisher","first-page":"e0175525","DOI":"10.1371\/journal.pone.0175525","volume":"12","author":"R Chlibek","year":"2017","unstructured":"Chlibek R, Smetana J, Sosovickova R, Gal P, Dite P, Stepanova V, Pliskova L, Plisek S. Prevalence of hepatitis C virus in adult population in the Czech Republic\u2014time for birth cohort screening. PLoS ONE. 2017;12(4):e0175525.","journal-title":"PLoS ONE"},{"key":"519_CR8","unstructured":"https:\/\/www.drogy-info.cz\/data\/obj_files\/32962\/837\/VZdrogy2017_web181207.pdf."},{"issue":"3 Suppl 1","key":"519_CR9","first-page":"2S","volume":"26","author":"DW Powell","year":"1997","unstructured":"Powell DW, Abramson BZ, Balint JA, Belle S, Bloomer JR, Diehl AK, Frakes JT, Garcia-Tsao G, Hook EW, Lusher JM, Popovsky MA. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997;26(3 Suppl 1):2S-10S.","journal-title":"Hepatology"},{"issue":"3","key":"519_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","volume":"33","author":"SH Mehta","year":"2008","unstructured":"Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126\u201333.","journal-title":"J Community Health"},{"key":"519_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.drugpo.2017.05.022","volume":"47","author":"J Iversen","year":"2017","unstructured":"Iversen J, Grebely J, Catlett B, Cunningham P, Dore GJ, Maher L. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. Int J Drug Policy. 2017;47:77\u201385.","journal-title":"Int J Drug Policy"},{"issue":"8","key":"519_CR12","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/liv.14043","volume":"39","author":"ME Socias","year":"2019","unstructured":"Socias ME, Ti L, Wood E, Nosova E, Hull M, Hayashi K, Debeck K, Milloy MJ. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. Liver Int. 2019;39(8):1400\u20137.","journal-title":"Liver Int"},{"key":"519_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.drugalcdep.2018.11.026","volume":"195","author":"JI Tsui","year":"2019","unstructured":"Tsui JI, Miller CM, Scott JD, Corcorran MA, Dombrowski JC, Glick SN. Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle. Drug Alcohol Depend. 2019;195:114\u201320.","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 2","key":"519_CR14","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1093\/cid\/cit271","volume":"57","author":"P Bruggmann","year":"2013","unstructured":"Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis. 2013;57(Suppl 2):S56-61.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"519_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.7326\/M16-0816","volume":"165","author":"GJ Dore","year":"2016","unstructured":"Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, et al. Elbasvir\u2013Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625\u201334.","journal-title":"Ann Intern Med"},{"issue":"3","key":"519_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","volume":"3","author":"J Grebely","year":"2018","unstructured":"Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3(3):153\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"S1","key":"519_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hep.30256","volume":"68","author":"S Kattakuzhy","year":"2018","unstructured":"Kattakuzhy S, Mathur P, Gross C, Silk R, Hil K, Nussdorf L, Chaudhury CS, Sternberg D, Masur H, Kottilil S, et al. High SVR in PWID with HCV despite imperfect medication adherence: data from the anchor study. Hepatology. 2018;68(S1):1\u2013183.","journal-title":"Hepatology"},{"key":"519_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","volume":"69","author":"EASL","year":"2018","unstructured":"EASL. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69:154\u201381.","journal-title":"J Hepatol"},{"key":"519_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jsat.2019.01.021","volume":"100","author":"O Falade-Nwulia","year":"2019","unstructured":"Falade-Nwulia O, Irvin R, Merkow A, Sulkowski M, Niculescu A, Olsen Y, Stoller K, Thomas DL, Latkin C, Mehta SH. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. J Subst Abuse Treat. 2019;100:45\u201351.","journal-title":"J Subst Abuse Treat"},{"key":"519_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/jvh.13214","volume":"27","author":"C Phillips","year":"2019","unstructured":"Phillips C, Schulkind J, O\u2019Sullivan M, Edelman N, Smith HE, Verma S, Jones CJ. Improving access to care for people who inject drugs: qualitative evaluation of project ITTREAT\u2014an integrated community hepatitis C service. J Viral Hepat. 2019;27:176\u201387.","journal-title":"J Viral Hepat"},{"issue":"5","key":"519_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/joim.12740","volume":"283","author":"S Olafsson","year":"2018","unstructured":"Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann OM, Hansdottir I, Bjornsson ES, Johannsson B, Sigurdardottir B, Fridriksdottir RH, Love A, et al. Treatment as Prevention for Hepatitis C (TraP Hep C)\u2014a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med. 2018;283(5):500\u20137.","journal-title":"J Intern Med"},{"issue":"27","key":"519_CR22","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599\u2013607.","journal-title":"N Engl J Med"},{"key":"519_CR23","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"519_CR24","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608\u201317.","journal-title":"N Engl J Med"},{"issue":"20","key":"519_CR25","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879\u201388.","journal-title":"N Engl J Med"},{"issue":"2","key":"519_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis. J Hepatol. 2017;67(2):263\u201371.","journal-title":"J Hepatol"},{"issue":"3","key":"519_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","volume":"70","author":"R D'Ambrosio","year":"2019","unstructured":"D\u2019Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, Soria A, Gatti F, Menzaghi B, Aghemo A, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):379\u201387.","journal-title":"J Hepatol"},{"issue":"8","key":"519_CR28","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/apt.15222","volume":"49","author":"T Berg","year":"2019","unstructured":"Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, Konig B, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther. 2019;49(8):1052\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"519_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.14735\/amgh201858","volume":"72","author":"J Skoup\u00e1","year":"2018","unstructured":"Skoup\u00e1 J, Urb\u00e1nek P. A comparison of cost-effectiveness analysis of two strategies\u2014immediate and delayed initiation of treatment of hepatitis C in the Czech Republic. Gastroenterol Hepatol. 2018;72(1):58\u201365.","journal-title":"Gastroenterol Hepatol"},{"key":"519_CR30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/TCRM.S133983","volume":"13","author":"J Sperl","year":"2017","unstructured":"Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, Spicak J. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Ther Clin Risk Manag. 2017;13:733\u20138.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"519_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1159\/000488965","volume":"43","author":"J Sperl","year":"2018","unstructured":"Sperl J, Kreidlova M, Merta D, Chmelova K, Senkerikova R, Frankova S. Paritaprevir\/ritonavir\/ombitasvir plus dasabuvir regimen in the treatment of genotype 1 chronic hepatitis C infection in patients with severe renal impairment and end-stage renal disease: a real-life cohort. Kidney Blood Press Res. 2018;43(2):594\u2013605.","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"519_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.14735\/amgh2019101","volume":"73","author":"P Urbanek","year":"2019","unstructured":"Urbanek P, Frankova S, Husa P, Sperl J, Plisek S, Roznovsky L, Kumpel P. Standard diagnostic and therapeutic approach to chronic hepatitis C virus (HCV) infection\u2014guidelines. Gastroenterol Hepatol. 2019;73(2):101\u201325.","journal-title":"Gastroenterol Hepatol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00519-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00519-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00519-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T09:09:00Z","timestamp":1625044140000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00519-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00519-y","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"31 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Thomayer's Hospital and the Institute for Clinical and Experimental Medicine, Prague, Czech Republic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}